Trade

with

Gilead Sciences Inc
(NASDAQ: GILD)
AdChoices
110.77
+3.60
+3.36%
After Hours :
-
-
-

Open

107.53

Previous Close

107.17

Volume (Avg)

10.34M (14.44M)

Day's Range

106.60-111.47

52Wk Range

63.50-111.47

Market Cap.

162.02B

Dividend Rate ( Yield )

-

Beta

0.77

Shares Outstanding

1.51B

P/E Ratio (EPS)

24.27 (4.42)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 11.20B

    • Net Income

    • 3.07B

    • Market Cap.

    • 162.02B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 42.80

    • PEG (Price/Earnings Growth) Ratio

    • 0.28

    • Beta

    • 0.77

    • Forward P/E

    • 10.96

    • Price/Sales

    • 10.38

    • Price/Book Value

    • 10.07

    • Price/Cash flow

    • 23.87

      • EBITDA

      • 4.86B

      • Return on Capital %

      • 27.73

      • Return on Equity %

      • 54.91

      • Return on Assets %

      • 27.73

      • Book Value/Share

      • 10.64

      • Shares Outstanding

      • 1.51B

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 131.00

        • Credit Rating

        • A+

        • Analysts

        • 8

        • EPS Estimate

        • 9.57

        • Cashflow Estimate

        • 9.58

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 136.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 18.60

          • 17.04

          • Net Income

            Q/Q (last year)

          • 373.20

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 15.99

          • 63.43

          • Net Income

            5-Year Annual Average

          • 8.90

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 81.20

            • 82.75

            • Pre-Tax Margin

            • 54.19

            • 39.38

            • Net Profit Margin

            • 42.80

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 75.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 43.50

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 32.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.49

              • 0.76

              • Current Ratio

              • 2.49

              • 2.92

              • Quick Ratio

              • 1.96

              • 2.35

              • Interest Coverage

              • 30.04

              • 38.02

              • Leverage Ratio

              • 1.94

              • 2.21

              • Book Value/Share

              • 10.64

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 23.15

                • 243.90

                • P/E Ratio 5-Year High

                • 25.04

                • 634.30

                • P/E Ratio 5-Year Low

                • 3.59

                • 124.82

                • Price/Sales Ratio

                • 9.90

                • 9.29

                • Price/Book Value

                • 9.61

                • 8.39

                • Price/Cash Flow Ratio

                • 23.87

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 54.91

                    (40.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 27.73

                    (21.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 34.89

                    (27.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 1.22M

                  • 117.08k

                  • Inventory Turnover

                  • 1.64

                  • 1.48

                  • Asset Turnover

                  • 0.65

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  4.52B
                  Operating Margin
                  40.39
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  23.87
                  Ownership

                  Institutional Ownership

                  94.65%

                  Top 10 Institutions

                  38.84%

                  Mutual Fund Ownership

                  54.40%

                  Float

                  99.44%

                  5% / Insider Ownership

                  0.56%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • VA CollegeAmerica Growth Fund of America

                  •  

                    51,949,548

                  • -13.02

                  • 3.44

                  • VA CollegeAmerica Invmt Co of America

                  •  

                    30,277,200

                  • -5.51

                  • 2.00

                  • Vanguard Total Stock Mkt Idx

                  •  

                    24,778,846

                  • -0.63

                  • 1.64

                  • VA CollegeAmerica Cap World Gr and Inc

                  •  

                    21,455,025

                  • -7.21

                  • 1.42

                  • VA CollegeAmerica AMCAP

                  •  

                    16,678,626

                  • -12.71

                  • 1.10

                  • Fidelity® Contrafund® Fund

                  •  

                    16,039,802

                  • 9.69

                  • 1.06

                  • Vanguard Five Hundred Index Fund

                  •  

                    15,693,603

                  • -1.33

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    15,314,958

                  • -2.60

                  • 1.01

                  • T. Rowe Price Growth Stock Fund

                  •  

                    15,308,500

                  • -1.13

                  • 1.00

                  • SPDR® S&P 500 ETF

                  •  

                    14,880,461

                  • 1.58

                  • 0.98

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Capital Research Global Investors

                  •  

                    137,780,654

                  • +12.12%

                  • 9.03

                  • Fidelity Management and Research Company

                  •  

                    93,532,784

                  • -6.62%

                  • 6.13

                  • Vanguard Group, Inc.

                  •  

                    78,741,071

                  • +1.88%

                  • 5.16

                  • T. Rowe Price Associates, Inc.

                  •  

                    66,996,617

                  • -9.35%

                  • 4.39

                  • State Street Corp

                  •  

                    61,526,594

                  • +0.68%

                  • 4.03

                  • BlackRock Fund Advisors

                  •  

                    46,520,382

                  • -0.33%

                  • 3.05

                  • Capital World Investors

                  •  

                    38,606,410

                  • -5.72%

                  • 2.53

                  • Goldman, Sachs & Co.

                  •  

                    24,799,058

                  • +54.95%

                  • 1.63

                  • Wellington Management Company, LLP

                  •  

                    22,390,888

                  • -26.17%

                  • 1.47

                  • Northern Trust Investments, N.A.

                  •  

                    21,663,917

                  • -0.82%

                  • 1.42

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Classic Growth

                  Style

                  Large Growth

                  Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new disco...morevery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company’s products comprise Truvada is an oral formulation dose...mored once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company’s products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company’s products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors; ease of patient compliance; patent protection; ease of use; price; insurance and other reimbursement coverage; distribution; and marketing. The Company owns various trademarks and trade names used in its business, including the following: GILEAD(r), GILEAD SCIENCES(r), TRUVADA(r), VIREAD(r), HEPSERA(r), AMBISOME(r), EMTRIVA(r), VISTIDE(r), LETAIRIS(r), VOLIBRIS(tm), RANEXA(r) and CAYSTON(r). The Company’s operations and activities are subject to extensive regulation by numerous government authorities in the United States and other countries.lessless

                  Key People

                  Dr. John C. Martin,M.D.

                  CEO/Chairman of the Board/Director

                  Ms. Robin L. Washington

                  CFO/Chief Accounting Officer/Executive VP

                  Mr. Gregg H. Alton

                  Executive VP, Divisional/Secretary

                  Dr. Norbert W. Bischofberger, PhD

                  Executive VP, Divisional/Chief Scientific Officer

                  Mr Paul Rutherford Carter

                  Executive VP, Divisional

                  • Gilead Sciences Inc

                  • 333 Lakeside Drive

                  • Foster City, CA 94404

                  • USA.Map

                  • Phone: +1 650 574-3000

                  • Fax: +1 650 578-9264

                  • gilead.com

                  Incorporated

                  1987

                  Employees

                  6,100

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: